Arcus Biosciences, Inc.

Key metrics

Financial performance

Over the last 8 fiscal years Arcus Biosciences, Inc.'s revenue grew from $1.41M to $247.00M, a compound annual growth rate of 90.7%. Net profit margin expanded from -3756.7% to -142.9% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (580 filings)

Recent press releases

• Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthc...2026-05-26

  Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET.

• Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pi...2026-04-21

  _Arcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first HIF-2a inhibitor-based tyrosine kinase inhibitor (TKI)-free regimen in the first-line (1L) setting_

• Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financia...2026-02-26

  Investors interested in listening to the conference call may do so by dialing +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID: 304747896. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee/304747896. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

• Arcus Biosciences to Participate in Two Upcoming Investor Conferences2026-02-26

  Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in March:

• Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results an...2026-02-23

  _Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort_

Similar companies

The largest companies sharing Arcus Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).